Company news

Relmada Therapeutics, Inc. news in 2024

Relmada Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

December 8, 2024

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

December 3, 2024

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

November 13, 2024

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

November 6, 2024

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

November 3, 2024

Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

August 6, 2024

Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry

June 17, 2024

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 7, 2024

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

March 18, 2024

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024

March 11, 2024

Relmada Therapeutics Provides Corporate Update

January 3, 2024

Calls in 2024